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Introduction {#sec1}
============

DNA-damaging agents are a widely used group of prominent drugs of cancer treatment ([@bib2]). Among the commonly used DNA-damaging agents, which covalently modify DNA, for instance, cisplatin and oxaliplatin cross-link DNA bases ([@bib23]), whereas other agents, such as inhibitors of topoisomerases (camptothecin, etoposide, and doxorubicin) or antimetabolites (pyrimidine analog 5-fluorouracil), cause DNA damage by changing chromatin structure and topology or by interfering with DNA replication ([@bib27], [@bib32], [@bib38]). It has been well documented that DNA damage elicits diverse cellular responses such as DNA repair, cell-cycle arrest, and cell death ([@bib30], [@bib35]). Although the underlying molecular mechanisms of these cellular responses have been extensively studied, many aspects of DNA damage responses are not fully understood ([@bib6]).

Following DNA damage, a predominant outcome of affected cells is apoptosis ([@bib40], [@bib41]). DNA-damaging agents induce apoptosis by blocking DNA replication, which leads to the collapse of replication forks and double-strand breaks (DSBs). DSBs result in p53-dependent caspase activation and subsequent apoptosis. However, it is known that DNA damage could also trigger p53-independent, death domain kinase, RIPK1 (receptor-interacting protein kinase 1)-mediated cell death ([@bib1], [@bib18], [@bib19]). Recent evidence suggests that DNA-damaging agents induce not only apoptosis but also non-apoptotic death such as necroptosis and pyroptosis ([@bib49]). Particularly, although the mechanism of DNA damage-induced apoptosis has been well studied, the molecular regulation of other forms of DNA damage-induced cell death are still elusive ([@bib33], [@bib41]).

Necroptosis is a programmed, caspase-independent cell death that is morphologically similar to necrosis. For tumor necrosis factor (TNF)-induced necroptosis, the receptor interacting protein kinases, RIPK1 and RIPK3, and the mixed lineage kinase domain-like (MLKL) are the key mediators ([@bib7], [@bib16], [@bib42], [@bib55]). It is known that, after being phosphorylated by RIPK3, MLKL translocates to the plasma membrane and mediates the execution of necroptosis ([@bib4], [@bib3], [@bib48], [@bib50]). It has been shown that DNA damage could induce necroptosis and that RIPK1 and RIPK3 are essential for the process ([@bib31], [@bib36], [@bib44], [@bib50]). However, although it has been shown that RIPK1 mediates the formation of the cytosolic cell death complex, known as Ripoptosome ([@bib43]), it is not clear how RIPK1 is engaged in response to DNA damage.

Retinoic acid receptors (RARs), RARα, RARβ, and RARγ belong to the superfamily of nuclear hormone receptors and act as transcription factors after activation by retinoic acid ([@bib10], [@bib22]). RARs regulate the expression of a large number of genes that are critical for cell growth, differentiation, and cell death ([@bib26], [@bib28]). Although the localization of these RARs is predominantly nuclear, cytoplasmic localizations of RARs have been reported in some types of cells, but the function of the cytosolic RARs is unknown ([@bib15]). Our previous work demonstrated that cytoplasmic RARγ was essential for TNF-induced RIPK1-initiated apoptosis and necroptosis. RARγ is released from the nucleus to orchestrate the formation of the cytosolic death complexes and functions as a critical checkpoint of RIPK1-initiated cell death.

RARγ is the major RAR expressed in human and mouse epidermis, whereas very little expression of RARα and no expression of RARβ is seen in skin ([@bib11]). RARγ has been shown to be a tumor suppressor, as loss of RARγ predisposed skin to tumors ([@bib5], [@bib8], [@bib9]). In addition, there is evidence that UV radiation from the sun induces a dramatic decrease in RARγ by proteasomal degradation resulting in premature skin aging and skin cancer ([@bib5], [@bib46]). However, the role of RARγ in skin cancer development is not well studied.

Here, we report that RARγ has a critical role in DNA damage-induced necroptotic cell death. We show that loss of RARγ abolishes the necroptosis induced by DNA-damaging agents. Furthermore, RARγ-null MEFs are less susceptible to apoptosis induced by DNA-damaging agents. We demonstrate that the involvement of RARγ in DNA damage-induced necroptosis and apoptosis is mediated through RIPK1 and that RARγ does not play a role in the intrinsic apoptosis triggered by DNA damage. This study reveals that RARγ is a critical component of DNA damage-induced cell death. Furthermore, we demonstrate that significant decrease in RARγ expression in the human squamous cell carcinoma (SCC) compared with normal skin and the loss of RARγ in keratinocytes leads to resistance to DNA-damaging drugs. Therefore, RARγ could be used as a chemotherapeutic marker for cancers.

Results {#sec2}
=======

DNA-Damaging Compounds Induce RIPK1-Dependent Necroptosis in MEFs {#sec2.1}
-----------------------------------------------------------------

It has been reported that DNA-damaging agents could induce necroptosis and trigger both extrinsic and intrinsic apoptotic pathways in certain types of cells ([@bib14], [@bib21], [@bib24], [@bib29], [@bib34]). To study the mechanisms of DNA damage-induced cell death, we first examined if these cell death pathways are activated in mouse embryonic fibroblasts (MEFs) in response to DNA damage by checking the commonly used markers for these pathways, MLKL phosphorylation for necroptosis, Caspase-9 (Casp-9) for intrinsic apoptosis, and Caspase-8 (Casp-8) for extrinsic apoptosis ([@bib17], [@bib25], [@bib36], [@bib48]). MEF cells were treated with DNA-damaging agents, cisplatin or etoposide and were collected to examine these proteins by immunoblotting at the indicated times ([Figure 1](#fig1){ref-type="fig"}A). As shown in [Figure 1](#fig1){ref-type="fig"}A, all three cell death pathways are activated by cisplatin or etoposide. Interestingly, among these three cell death pathways, necroptosis appears to be engaged first, followed by the activation of extrinsic apoptosis. The engagement of intrinsic apoptosis is significantly slower compared with the other two. These results suggest that DNA damage induced both necroptosis and apoptosis, with necroptosis and extrinsic apoptosis preceding intrinsic apoptosis, in MEF cells.Figure 1DNA-Damaging Compounds Induce Both RIPK1-Dependent Apoptotic and Necroptotic Cell Death(A) MEF WT cells were treated with cisplatin (left panel) or etoposide (right panel) for the indicated time. Cell lysates were analyzed by immunoblotting as indicated.(B) *Ripk1*^+/+^ and *Ripk1*^−/−^ cells were treated with cisplatin (left panel) or etoposide (right panel) for the indicated time. Cell lysates were analyzed by immunoblotting as indicated.(C) *Ripk1*^+/+^ and *Ripk1*^−/−^ cells were treated with cisplatin 50 μM (left panel) or etoposide 50 μM (right panel) for the indicated time period, and cell death analysis was determined by propidium iodide staining and analyzed by flow cytometry. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.All blots above are representative of one of three experiments. Results shown are averages ± SEM from three independent experiments. ∗∗p \< 0.01, ∗∗∗p \< 0.001.

As RIPK1 is known to be a key player in DNA damage-induced necroptosis and apoptosis ([@bib1], [@bib18], [@bib19]), we then examined the involvement of RIPK1 in the phosphorylation of MLKL and the activation of the extrinsic and intrinsic apoptotic pathways using wild-type (WT) (*Ripk1*^+/+^) and RIPK1-null (*Ripk1*^−/−^) MEFs. Cells were treated with cisplatin or etoposide and were then collected for western blot. As shown in [Figure 1](#fig1){ref-type="fig"}B, consistent with previous findings, RIPK1 is essential for cisplatin or etoposide-induced MLKL phosphorylation. Interestingly, we found that whereas Casp-8 activation was significantly impaired and delayed, activation of Casp-9 by these two drugs was not affected by the deletion of RIPK1 ([Figure 1](#fig1){ref-type="fig"}B). These results suggest that the engagement of necroptosis and extrinsic apoptosis were both mediated by RIPK1, which does not play any role in the intrinsic apoptotic pathway. These conclusions were further supported by measuring DNA damage-induced cell death in these cells. As shown in [Figure 1](#fig1){ref-type="fig"}C, loss of RIPK1 only partially blocked DNA damage-induced cell death because deletion of RIPK1 has no effect on Casp-9 activation. Consistently, RIPK3 and MLKL deletion also partially blocked DNA damage-induced cell death and the phosphorylation of MLKL ([Figure S1](#mmc1){ref-type="supplementary-material"}).

RARγ Plays a Role in DNA Damage-Induced Necroptosis and Extrinsic Apoptosis {#sec2.2}
---------------------------------------------------------------------------

Recently, we reported that the nuclear receptor, RARγ, plays a key role in RIPK1-mediated tumor necrosis factor (TNF)-induced cell death ([@bib53]). As RIPK1 mediates DNA damage-induced necroptosis and extrinsic apoptosis, we then tested the role of RARγ in DNA damage-induced cell death. To do so, the WT (*Rarγ*^+/+^) and RARγ-null (*Rarγ*^−/−^) MEFs ([Figure S2](#mmc1){ref-type="supplementary-material"}A) were treated with cisplatin or etoposide and collected for examining the phosphorylation of MLKL and the activation of Casp-8 and Casp-9. As shown in [Figures 2](#fig2){ref-type="fig"}A and 2B, similar to that observed with RIPK1 deficiency, deletion of RARγ led to the abolishment of MLKL phosphorylation and the impaired activation of Casp-8, but had no effect on Casp-9 activation in response to DNA damage. Consistent with the results of MLKL phosphorylation and the activation of Casp-8 and Casp-9, loss of RARγ partially protected cells against DNA damage-induced cell death when compared with that observed in WT MEFs by cisplatin or etoposide ([Figure 2](#fig2){ref-type="fig"}C) or other DNA-damaging agents ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To confirm that the resistance of *Rarγ*^−/−^ MEFs to DNA-damaging agents is due to the loss of RARγ, RARγ was reintroduced back to *Rarγ*^−/−^ MEFs. The ectopic expression of RARγ restored the sensitivity of the cells to cisplatin or etoposide ([Figure 2](#fig2){ref-type="fig"}D). We also examined the role of RARγ in DNA damage-induced cell death in human HT29 cancer cells. As shown in [Figure S3](#mmc1){ref-type="supplementary-material"}, we found that DNA damage-induced cell death, the phosphorylation of MLKL, and the activation of Casp-8 are significantly decreased in RARγ knockdown HT29 (RARγ-short haprpin RNA \[shRNA\]) cells compared with WT control-shRNA HT29 cells following cisplatin treatment, whereas Casp-9 activation is not affected. These results are similar to what we observed in *Rarγ*^+/+^ and *Rarγ*^−/−^ MEFs ([Figures 2](#fig2){ref-type="fig"}A--2C). We next tested if the partial protection against DNA damage-induced cell death in RARγ-null cells is due to the activation of caspases. To do so, we pre-treated *Rarγ*^*+/+*^ and *Rarγ*^*−/−*^ cells with the caspase inhibitor z-VAD-fmk (zVAD) and a Casp-9-specific inhibitor, zLEHD, because zVAD does not block Casp-9 activation efficiently ([@bib39]), followed by cisplatin or etoposide treatment. As shown in [Figure 3](#fig3){ref-type="fig"}A, although zVAD treatment did increase the survival of RARγ-null cells, the combined treatment of zVAD and zLEHD almost completely blocked cell death triggered by cisplatin or etoposide in RARγ^−/−^ cells. However, these caspase inhibitors only partially protected WT cells against cell death induced by cisplatin and etoposide ([Figure 3](#fig3){ref-type="fig"}A). The remaining DNA damage-induced cell death of the WT MEF cells with pre-treatment of both zVAD and zLEHD is due to the activation of the necroptotic pathway because treating these WT cells with the specific RIPK1 inhibitor, necrostatin-1, completely blocked cell death induced by cisplatin or etoposide ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). In addition, as shown in [Figures 3](#fig3){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}C, treatment with caspase inhibitors blocked caspase activation, but had no effect on MLKL phosphorylation. Taken together, these results suggest that RARγ is essential for DNA damage-induced necroptosis and is involved in extrinsic, but not intrinsic, apoptosis induced by DNA-damaging compounds.Figure 2RARγ Is Required for DNA Damage-Induced Necroptosis and Extrinsic Apoptosis(A and B) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were treated with cisplatin (left panels) or etoposide (right panels) for the indicated time. Cell lysates were analyzed by immunoblotting as indicated. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(C) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were treated with cisplatin 50 μM (left panel) or etoposide 50 μM (right panel) for the indicated time period, and cell death analysis was determined by propidium iodide staining and analyzed by flow cytometry. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(D) *Rarγ*^+/+^, *Rarγ*^−/−^, and *Rarγ*^−/−^ + WT-RAR*γ* cell lysates were analyzed by immunoblotting as indicated (upper panel). *Rarγ*^+/+^, *Rarγ*^−/−^, and *Rarγ*^−/−^ + WT-RAR*γ* cells were treated with cisplatin 50 μM (lower left panel) or etoposide 50 μM (lower right panel) for the indicated time period, and cell death analysis was determined by popidium iodide staining and analyzed by flow cytometry.All blots above are representative of one of three experiments. Results shown are averages ± SEM from three independent experiments. ∗∗p \< 0.01, ∗∗∗p \< 0.001.Figure 3Caspase Inhibitors Block DNA Damage-Induced Cell Death in RARγ-KO Cells(A) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were pre-treated for 30 min with or without z-VAD-fmk (zVAD), zLEHD, or combined treatments as indicated followed by treatment with cisplatin 50 μM (left panel) or etoposide 50 μM (right panel) for 36 h. Cell survival was determined by propidium iodide (PI) staining and analyzed by flow cytometry.(B) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were pre-treated for 30 min with or without zVAD, zLEHD, NEC1, or combined treatments as indicated followed by treatment with cisplatin 50 μM (left panel) or etoposide 50 μM (right panel) for 36 h. Cell survival was determined by PI staining and analyzed by flow cytometry.(C) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were pre-treated for 30 min with or without combined z-VAD-fmk (zVAD) and zLEHD followed by treatment with cisplatin (left panel) or etoposide (right panel) for 20 h. Cell lysates were analyzed by immunoblotting as indicated. All blots above are representative of one of three experiments. See also [Figure S4](#mmc1){ref-type="supplementary-material"}. Results shown are averages ± SEM from three independent experiments. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

It is known that DNA-damaging compounds could trigger the autocrine production of TNFα in cells ([@bib1], [@bib52], [@bib54]). It has been suggested that the secreted TNFα contributes to DNA damage-induced necroptosis in mouse L929 cells ([@bib54]). Therefore, to examine the effect of the secreted TNFα in DNA damage-induced necroptosis in MEFs, we examined if TNFα is produced in response to DNA damage in *Rarγ*^+/+^ and *Rarγ*^−/−^ MEFs. We found that cisplatin or etoposide treatment leads to the production of TNFα at similar levels in *Rarγ*^+/+^ and *Rarγ*^−/−^ MEFs ([Figure S5](#mmc1){ref-type="supplementary-material"}A). These results suggest that DNA damage induces the production of TNFα in MEFs and RARγ is not involved in the production of TNFα. To investigate the involvement of autocrine TNFα in DNA damage-induced cell death, we then examined the cisplatin- or etoposide-induced cell death, MLKL phosphorylation and the activation of Casp-8 and Casp-9 in *Tnfr1*^+/+^ and *Tnfr1*^−/−^ MEFs. As shown in [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C, there is no difference in cell death, MLKL phosphorylation and the activation of Casp-8 and Casp-9 in *Tnfr1*^+/+^ and *Tnfr1*^−/−^ MEFs. Therefore, these results suggest that although DNA damage induces TNFα production, TNF signaling does not contribute to DNA damage-induced cell death in MEFs.

RARγ Is Required for RIPK1 to Initiate Necroptosis in Response to DNA Damage {#sec2.3}
----------------------------------------------------------------------------

To further investigate the involvement of RARγ in DNA damage-induced necroptosis, we next examined whether RARγ is required for RIPK1 to initiate the formation of the necrosome complex (Ripoptosome) in response to DNA damage. We previously reported that RARγ is critical for RIPK1 to initiate the formation of Ripoptosome triggered by TNF ([@bib53]). Specifically, we found that RARγ and RIPK1 formed an intermediate complex initially in response to induction of necroptosis by treatment with TSZ (TNF, Smac mimetic, z-VAD-fmk) and that RARγ was not present in the final necrosome complex when RIPK3 was recruited ([@bib53]). Therefore, we first tested if RARγ and RIPK1 form a complex in response to DNA damage by immunoprecipitating RARγ. As shown in [Figure 4](#fig4){ref-type="fig"}A, immunoprecipitating RARγ efficiently pulled RIPK1, but not RIPK3, following cisplatin treatment. To examine the recruitment of RIPK3 to the necrosome by RIPK1, we performed immunoprecipitation experiments with an anti-Casp-8 antibody as we and others have reported previously ([@bib7], [@bib47], [@bib53]). As shown in [Figure 4](#fig4){ref-type="fig"}B, immunoprecipitating caspase 8 from lysates of cisplatin-treated WT MEFs efficiently pulled down both RIPK1 and RIPK3. However, Casp-8 immunoprecipitation failed to pull down either of RIPK1 and RIPK3 from lysates of cisplatin-treated *Rarγ*^*−/−*^ cells. However, as we found previously, RARγ was not present in the necrosome complex pulled down by immunoprecipitating Casp-8. Therefore, these results suggest that RARγ is essential for RIPK1 to initiate the formation of the necrosome induced by DNA-damaging agents.Figure 4Cytosolic RARγ Is Required for RIPK1 to Initiate Necroptosis in Response to DNA Damage(A) *Rarγ*^+/+^ cells were treated with cisplatin for the indicated time period. Cell lysates were collected and immunoprecipitated with anti-RARγ antibody. The immunoprecipitated complexes were immunoblotted with the indicated antibodies.(B) *Rarγ*^+/+^ and *Rarγ*^−/−^ cells were treated with cisplatin for the indicated time period. Cell lysates were collected and immunoprecipitated with anti-caspase 8 antibody. The immunoprecipitated complexes were immunoblotted with the indicated antibodies. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.(C) Confocal microscopy of WT MEFs transfected with GFP- RARγ plasmid and treated with cisplatin, and images were captured in the indicated time period (blue, DAPI; green, RARγ). Images are representative of one of three experiments. Scale bar, 10 μm.(D) Cellular fractionation of *Rarγ*^+/+^ cells treated with DMSO or cisplatin 50 μM for 6 h was performed. Total (T), cytosolic (C), and nuclear (N) fractions were analyzed by immunoblotting with the indicated antibodies. All blots and images above are representative of one of three experiments.

In our earlier study, we demonstrated that RARγ was released to the cytoplasm from the nucleus during TSZ-induced necroptosis ([@bib53]). We then examined the cellular localization of RARγ during the process of DNA damage-induced necroptosis. First, we transfected WT MEFs cells with a green fluorescent protein (GFP)-tagged RARγ plasmid and found that the GFP-RARγ protein almost exclusively localized in the nucleus in non-treated cells ([Figure 4](#fig4){ref-type="fig"}C). Interestingly, cisplatin treatment caused a dramatic increase of GFP-RARγ presence in the cytoplasm after 6-h treatment and this release of RARγ to the cytosol occurs parallel with the formation RARγ and RIPK1 complex ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, we confirmed the release of the endogenous RARγ from the nucleus by cell fractionation and western blot ([Figure 4](#fig4){ref-type="fig"}D). These results indicated that RARγ was released to the cytoplasm from the nucleus and facilitates RIPK1 to initiate necroptosis in response to DNA damage.

Loss of RARγ Blocks DNA Damage-Induced Necroptosis in Keratinocytes and Promotes Carcinogen-Induced Papilloma {#sec2.4}
-------------------------------------------------------------------------------------------------------------

RARγ was found to be highly expressed in keratinocytes and its expression is decreased in skin cancers ([@bib8], [@bib12], [@bib51]). Early studies also suggested that RARs may play a role in skin tumor development and that RARγ may function as a tumor suppressor ([@bib5], [@bib11]). To study the role of RARγ-mediated cell death in skin cancer development, we first checked RARγ and RARα expression in human SCC samples and found that the expression of RARγ, but not RARα, is dramatically decreased in all cancer samples compared with normal adjacent tissues ([Figure 5](#fig5){ref-type="fig"}A). Our findings are consistent with previous reports and support that RARγ may function as a tumor suppressor in skin cancer development. However, the underlying mechanism of RARγ′s role in skin tumorigenesis is largely unknown.Figure 5RARγ Required for DNA Damage-Induced Necroptosis in Keratinocytes and Promotes Carcinogen-Induced Papilloma(A) Immunostaining of paraffin-embedded human SCC tumors and adjacent normal skin sections from human biopsy samples. Sections were stained with H&E or immunohistochemically stained with anti-RARγ or anti-RARα antibodies.(B) Primary keratinocytes from *Rarγ* 1^+/+^ and *Rarγ* 1^−/−^ mice were treated with DMBA or vehicle (acetone) for 5 days. Popidium iodide-positive population of cells mentioned above was determined by flow cytometry.(C) Primary keratinocytes from RARγ1^+/+^ and RARγ1^−/−^ mice were treated with DMBA or acetone for the indicated time. Cell lysates were analyzed by immunoblotting as indicated.(D) *Rarγ* 1^+/+^ and *Rarγ1*^−/−^ mice were treated with a single topical application of DMBA for 24 h, and the skin was collected. Skin sections were stained with H&E or immunohistochemically stained with anti-p-MLKL antibody. Right panel, the p-MLKL-positive cells were counted for 1 mm linear length of the epidermis.(E) *Rarγ1*^+/+^ and *Rarγ* 1^−/−^ mice were treated with a single topical application of DMBA followed 2 weeks later by twice weekly topical applications of TPA for 33 weeks. The number and size of papillomas on each mouse were recorded every 1 week. The average number of papillomas (more than 2 mm in diameter) per mouse is plotted versus the number of weeks post-initiation (left panel). Average papilloma size (in mm) was recorded for *Rarγ1*^+/+^ and *Rarγ*1^−/−^ mice (right panel). See also [Figure S6](#mmc1){ref-type="supplementary-material"}.All blots and images above are representative of one of three experiments. Scale bar, 50 μm. Results shown in graphs are averages ± SEM from three independent experiments. ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001.

To explore the possible involvement of RARγ-mediated necroptosis in tumorigenesis, we employed the well-established initiation and promotion two-stage skin carcinogenesis mouse model. In this model, mice are first subjected to a single topical application of the carcinogen 7, 12-dimethylbenz\[a\]-anthracene (DMBA), which initiates the formation of tumors. Initiation stage is followed by the promotion stage during which animals are treated twice a week with a pro-inflammatory agent 12-0-tetradecanoylphorbol 13-acetate (TPA). As DMBA is a known DNA adduct agent, we first examined if DMBA induces necroptosis in primary keratinocytes. To do so, we tested the effect of DMBA treatment on WT and RARγ1-knockout (KO) cells *in vitro*. As shown in [Figure 5](#fig5){ref-type="fig"}B, loss of RARγ resulted in significant protection of the cells against DMBA-induced cell death. Importantly, DMBA triggers necroptosis in WT keratinocytes, but not the RARγ-KO cells ([Figure 5](#fig5){ref-type="fig"}C). Then, we checked if DMBA induced necroptosis in keratinocytes *in vivo* by examining the effect of the topical treatment of DMBA in the epidermal layer in WT and RARγ1-KO mice. Both WT and RARγ1-KO littermates were treated with a single topical dose of DMBA for 1 day, and skin samples were collected for MLKL phosphorylation with an anti-phosphoryl-MLKL antibody ([@bib20]). As shown in [Figure 5](#fig5){ref-type="fig"}D, the epidermis of RARγ1-KO mice had no phosphoryl-MLKL-positive cells, whereas abundant positive cells of MLKL phosphorylation in the epidermis of WT mice were observed, suggesting that loss of RARγ protected skin epidermal cells from DMBA-induced necroptosis. To be sure that RARγ deletion does not affect the promotion of epidermal hyperplasia by TPA, we treated WT and RARγ1-KO littermates with three topical applications of TPA over 1 week, and skin was collected 48 h after the last treatment. The epidermal thickness, measured as the distance from the basal to the upper granular layer, was similar between WT and RARγ1-KO, confirming that loss of RARγ does not affect TPA-promoted epidermal growth ([Figure S3](#mmc1){ref-type="supplementary-material"}). Finally, we examined the effect of RARγ deletion on papilloma formation by treating both WT and RARγ1-KO littermates, generated in our previous study ([@bib53]), with a single topical dose of DMBA followed by twice weekly application of TPA for 32 weeks. As shown in [Figures 5](#fig5){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}B, papillomas appeared after 10 weeks of TPA promotion. However, by 17 weeks, RARγ1-KO mice had a significant increase in papilloma size when compared with WT mice and by 22 weeks, in papilloma number as well. By 32 weeks, the size and number of papillomas on RARγ1-KO mice are twice as large and more numerous compared with WT mice. Taken together, the above results imply that RARγ-mediated necroptosis may play a key role in limiting DMBA/TPA-induced papilloma formation and growth.

Discussion {#sec3}
==========

DNA-damaging compounds induce programmed cell death, such as apoptosis and necroptosis in diverse types of mammalian cells ([@bib14], [@bib24], [@bib29], [@bib40], [@bib41]). Although the molecular mechanism of DNA damage-induced apoptosis is well studied, the regulation of DNA damage-induced necroptosis is not fully understood. Our previous study defined a role for RARγ in RIPK1-initiated apoptosis and necroptosis ([@bib53]). Here, we found that the loss of RARγ rendered cells resistant to both RIPK1-initiated apoptosis and necroptosis induced by DNA-damaging compounds. Furthermore, we showed that treatment with DNA-damaging compounds leads to RARγ being released from the nucleus to the cytosol, which mediates the formation of the death complexes. We showed that RARγ is essential for RIPK1 and RIPK3 to form complex and the recruitment of pMLKL, which is activated by RIPK3 during necroptotic cell death in response to DNA damage.

Ours and others\' early studies demonstrated that RIPK1 is crucial for DNA damage-induced cell death ([@bib1], [@bib18], [@bib19]). In our current study, our results indicate that RARγ is critical for DNA damage-induced necroptosis and partial apoptotic pathway. We found that RIPK1 is essential for DNA damage-induced necroptosis and partially affects extrinsic apoptosis but not intrinsic apoptosis. Therefore, our work extended our understanding about the role of RIPK1 in DNA damage-induced cell death. Our current study suggests that whereas DNA damage induced both apoptosis and necroptosis, necroptosis and extrinsic apoptosis precede the intrinsic apoptotic pathway as the loss of RARγ leads to the delayed activation of caspase 8, the extrinsic apoptosis marker ([@bib14], [@bib17], [@bib25]), but has no effect on the activation of the intrinsic apoptosis marker caspase 9. These conclusions are supported by the result that the combined treatment of zVAD and zLEHD completely prevent the DNA damage-induced caspase activation.

An earlier study reported that TNFα was produced in response to DNA damage and contributed to DNA damage-induced necroptosis ([@bib54]). In this study, L929 cells were used that the secreted TNFα contributes to DNA damage-induced necroptosis. L929 cells are known to undergo necroptosis following TNFα treatment alone. However, TNFα alone does not trigger any cell death in MEF cells, which undergo TNF-induced necroptosis in the presence of Smac mimetic and z-VAD ([@bib45], [@bib56], [@bib57]). Although we also observed the production of TNFα following DNA damage, we did not observe any difference of cell death between WT and TNFR1 KO cells in response to DNA damage ([Figure S5](#mmc1){ref-type="supplementary-material"}). Our finding in MEFs is similar to that reported by Xu et al., in which they found that cisplatin-induced production of autocrine TNFα has no effect in cell death in the mouse proximal tubule cells ([@bib52]). In addition, we found that RARγ deletion does not affect the production of TNFα following DNA damage ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Previous studies found that the cytosolic death complex mediated by RIPK1, known as RIPoptosome, is responsible for DNA damage-induced necroptosis independently of all death factor and receptors ([@bib1], [@bib43]). Our current study provides insight about the formation of the RIPoptosome and demonstrated the critical role of RARγ in the formation of this cytosolic death complex in response to DNA damage. Therefore, DNA damage-induced necroptosis is mainly mediated by RARγ-orchestrated, cytosolic RIPK1/RIPK3 complex.

Previous studies suggest that RARγ may have a tumor suppressor role in skin tumor development ([@bib5], [@bib46]). Our study with human SCC biopsy samples supported this possibility as a significant decrease in RARγ expression is observed in cancer samples compared with normal skin tissues that express high levels of RARγ. Furthermore, our use of RARγ1-KO mice in a model of skin cancer showed that the lack of RARγ leads to a significant increase in the number and size of papillomas. Importantly, from the examination of the epidermal layer after treatment with of DMBA, we found that loss of RARγ protected keratinocytes and skin epidermal cells from DMBA-induced necroptosis *in vitro* and *in vivo,* respectively. These results imply that RARγ may function as a tumor suppressor by mediating necroptosis to limit tumor growth during skin cancer development. However, when solid tumors grow to certain sizes, the cells in the core of solid tumors will undergo necroptosis because of hypoxia and nutrient depletion. Our recent work found that necroptosis at this stage of solid tumors following the reprogramming of RIPK3 expression has a promoting effect on tumor metastasis ([@bib20]).The underlying mechanism of this metastasis-promoting effect of tumor necroptosis is under investigation.

Taken together, our present results provide evidence that RARγ plays a critical role in DNA damage-induced necroptosis and extrinsic apoptosis by modulating RIPK1-initiated formation of the death complexes. This study reveals that RARγ is a critical regulatory component of the DNA damage-induced apoptotic and necroptotic cell death. Finally, our work further supported the possible role of RARγ as a tumor suppressor and demonstrated that RARγ could potentially serve as a clinical marker for chemotherapy.

Limitations of the Study {#sec3.1}
------------------------

In this study, we examined the role of RARγ as a critical regulatory component of the DNA damage-induced apoptotic and necroptotic cell death. Our work examined the effect of RARγ in human and mouse skin cancer. However, a limitation of this study is that we did not examine the tumor suppressor function of RARγ in other types of cancer.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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